These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27470327)

  • 1. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers.
    Apostolova I; Ego K; Steffen IG; Buchert R; Wertzel H; Achenbach HJ; Riedel S; Schreiber J; Schultz M; Furth C; Derlin T; Amthauer H; Hofheinz F; Kalinski T
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2360-2373. PubMed ID: 27470327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC.
    Apostolova I; Rogasch J; Buchert R; Wertzel H; Achenbach HJ; Schreiber J; Riedel S; Furth C; Lougovski A; Schramm G; Hofheinz F; Amthauer H; Steffen IG
    BMC Cancer; 2014 Dec; 14():896. PubMed ID: 25444154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
    Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
    Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
    Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
    Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
    Lee JY; Choi JY; Heo JH; Han J; Jang SJ; Kim K; Kim J; Shim YM; Kim BT
    Nuklearmedizin; 2016; 55(1):7-14. PubMed ID: 26875430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Independent Prognostic Value of Asphericity of
    Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
    Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
    Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S
    Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
    Meng X; Sun X; Mu D; Xing L; Ma L; Zhang B; Zhao S; Yang G; Kong FM; Yu J
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):960-6. PubMed ID: 21440998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
    Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
    Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
    Kwon W; Howard BA; Herndon JE; Patz EF
    J Thorac Oncol; 2015 Jun; 10(6):897-902. PubMed ID: 25811445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.